Relationship of serum isoflavone, insulin and adiponectin levels with breast cancer risk

Breast Cancer

Volumn 22, Issue 5, 2015, Pages 452-461

  Minatoya, Machiko ^a   Kutomi, Goro ^a   Asakura, Sumiyo ^a   Otokozawa, Seiko ^a   Sugiyama, Yukiko ^a   Ohnishi, Hirofumi ^a   Akasaka, Hiroshi ^a   Miura, Tetsuji ^a   Mori, Mitsuru ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Breast cancer; Insulin; Isoflavones

Indexed keywords

ADIPONECTIN; DAIDZEIN; EQUOL; GENISTEIN; GLYCITEIN; INSULIN; ADIPOQ PROTEIN, HUMAN; ISOFLAVONE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; TREND STUDY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BREAST NEOPLASMS; CHEMISTRY; MIDDLE AGED; MOLECULAR WEIGHT; RISK FACTOR;

ADIPONECTIN; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENISTEIN; HUMANS; INSULIN; ISOFLAVONES; MIDDLE AGED; MOLECULAR WEIGHT; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS;

EID: 84940956824     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-013-0502-2     Document Type: Article

References (68)

1. Hirabayashi Y, Zhang M. Comparison of time trends in breast cancer incidence (1973–2002) in Asia, from cancer incidence in five continents, vols IV–IX. Jpn J Clin Oncol. 2009;39:411–2.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Soube T. Cancer incidence and incidence rates in Japan 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2011;41:139–47.
3. Yoshiike N, Seino F, Tajima S, Arai Y, Kawano M, Furuhata T, et al. Twenty-year changes in the prevalence of overweight in Japanese adults: the national nutrition survey 1976–95. Obes Rev. 2002;3:183–90.
4. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoids phytoestrogens. J Steroid Biochem Mol Biol. 1993;44:147–53.
5. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific kinases. J Biol Chem. 1987;262:5592–5.
6. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252–63.
7. Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. J Clin Oncol. 1998;28:360–3.
8. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet. 2001;2:133–40.
9. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body b size, and risk of postmenopausal breast cancer: the women’s Health Initiative (United States). Cancer Causes Control. 2002;13:741–51.
10. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
11. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer. 1992;52:511–6.
12. Del Goudice ME, Fantus IG, Ezzxat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998;47:111–20.
13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42–51.
14. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–8.
15. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.
16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.
17. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 2002;10:1104–10.
18. Rose DP, Komninou D, Stephensen GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65.
19. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.
20. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.
21. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2005;237:109–14.
22. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–75.
23. Clavel-Chapelon F, E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002;86:723–7.
24. van der Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom S, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514–27.
25. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007;22:117–21.
26. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370–9.
27. Körner A, Pazaitou-Panayioyou K, Kelesidis I, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007;92:1041–8.
28. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237:109–14.
29. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE, et al. Associations between adiponectin and two different cancers: breast and colon. Asian Pacific J Cancer Prev. 2012;13:395–8.
30. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92:1510–6.
31. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14:669–77.
32. Retnakaran R, Hanley AJ, Connelly PW, Maguire G, Sermer M, Zinman B. Low serum levels of high-molecular weight adiponectin in Indo-Asian women during pregnancy: evidence of ethnic variation in adiponectin isoform distribution. Diabetes Care. 2006;29:1377–9.
33. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Nat Can Inst. 1996;88:756–8.
34. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R, et al. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006;345:271–9.
35. Arditi JD, Venihaki M, Karalis KP, Chrous GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal like between obesity and cancer. Horm Metab Res. 2007;39:9–13.
36. Jardé T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, et al. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 2008;53:484–7.
37. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Boris Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem. 2001;276:38023–8.
38. Wang Y, Lam JB, Lam KSL, Liu J, Lam MC, Hoo RLC, et al. Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006;66:11462–70.
39. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res. 2005;28:1263–9.
40. Verheus M, van Gils CH, Keinan-Boker L, et al. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol. 2007;25:648–55.
41. Iwasaki M, Hamada GS, Nishimoto IN, et al. Dietary isoflavone intake and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat. 2009;116:401–11.
42. Iwasaki M, Inoue M, Otani T, Sasazaki S, Kurahashi N, Miura T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case–control study from the Japan public health center-based prospective study group. J Clin Oncol. 2008;26:1677–83.
43. Lampe JW. Emerging research on equol and cancer. J Nutr. 2010;140:1369S–72S.
44. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98:9–14.
45. Mathew A, Gajalakshimi V, Rajan B, Kanimozhi V, Brennan P, Mathew BC, et al. Anthropometric factors and breast cancer risk among urban and rural women in South India: a multicentric case–control study. Br J Cancer. 2008;99:207–13.
46. Wu MH, Chou YC, Yu JC, Yu CP, Wu CC, Chu CM, et al. Hormonal and body-size factors in relation to breast cancer risk: a prospective study of 11,889 women in a low-incidence area. Ann Epidemiol. 2006;16:223–9.
47. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:698–712.
48. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996;88:756–8.
49. Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med. 1999;8:1265–72.
50. Kaaks R, Lundin E, Manjer J, Rinaldi S, Biessy C, Söderberg S, et al. Prospective study of IGF-1, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes Control. 2002;13:307–16.
51. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol. 2002;156:349–68.
52. Muti P, Quattrin T, Grant BJB, Krogh V, Micheli A, Schünemann HJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev. 2002;11:1361–8.
53. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Ho GYF, Gunter MJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 2009;125:2704–10.
54. Ogasawara M, Sirbasku DA. A new serum-free method of measuring growth factor activities for human breast cancer cells in culture. In Vitro Cell Dev Biol. 1988;24:911–20.
55. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992;52:3924–30.
56. Gliozzo B, Sung CK, Scalia P, Papa V, Frasca F, Sciacca L, et al. Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells in mediated by a phosphatidylinositol-3-kinase- independent pathway. J Cellular Biochem. 1998;70:268–80.
57. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, AntoninoBelfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinol. 2012;153:2152–63.
58. Osborne CK, Monaco ME, Lippman ME, Kahn CR. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in longterm tissue culture. Cancer Res. 1987;38:94–102.
59. Sepp-Lorenzino L, Rosen N, Lebwohl DE. Insulin and insulin-like growth factor signaling are defective in the MDA-MB-468 human breast cancer cell line. Cell Growth Differ. 1994;5:1077–83.
60. Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, et al. Overexpression of membrane glycoprotein PC-1 in MDA-MB-231 breast cancer cells in associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol. 1996;10:1318–26.
61. Ward H, Chapelais G, Kuhnle GG, Ruben R, Khaw KT, Bingham S. European prospective into cancer-Norfolk cohort. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European prospective into Cancer-Norfolk cohort study. Breast Cancer Res. 2008;10:R32.
62. Oh S, Park CY, Lee E, Yoon Y, Lee E, Park S, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res. 2011;13:R34.
63. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–62.
64. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352–63.
65. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 2005;48:1084–7.
66. Hao G, Li W, Guo R, Yang JG, Wang Y, Tian Y, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis. 2013;228:29–35.
67. Mohamad AS, Taher AN, Mohamad AA, El-Nasr MS. Evaluation of serum adiponectin level in Egyptian breast cancer patients before and after treatment. Med J Cairo Univ. 2010;78:67–76.
68. Pfeiler G, Konigsberg R, Hadji P, Fitzal F, Tea MKM, Vogl S, et al. The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer. J Clin Oncol (meeting abstracts). 2013;31(suppl):e11601.